Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (91)	6/8/2009 4:56:22 PM
From: Arthur Radley	Respond to of 196

The AZN deal might be the case of selling more than the first born baby, however, maybe at the time it was the best deal that was available for them. There is no doubt that AZN is holding the winning hand on the future of this drug.......if the Phase III can replicate this current data. With that said.......I get a little nervous with data being based on 16 people. Based on the ALL trial I had placed a market cap of $400M (2X Revenue) and by discounting back by 15% a year until the first revenue(2012) comes in.....a price tag of $5.65 for the stock. With the price action today and heavy bidding on the stock I cut back by 75% on my holdings. Between now and the next data release(August) the stock will probably drift down......the close today sure didn't express much faith in the stock. ARQL seems to be getting some attention....bouncing off new 52 week high.